Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.
Eli Lilly and Company (NYSE: LLY) generates frequent news across cardiometabolic health, oncology, immunology, obesity and manufacturing expansion. This page aggregates recent press releases and third-party coverage so readers can follow how Lilly’s medicines, clinical programs and corporate actions are evolving over time.
Recent updates show Lilly reporting Phase 3 results for multiple late-stage assets. In obesity and cardiometabolic health, the company has shared topline data from ATTAIN-MAINTAIN, a Phase 3 trial of orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for weight maintenance after prior treatment with injectable incretin therapies. Lilly has also reported results from TRIUMPH-4, a Phase 3 trial of retatrutide, an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight and knee osteoarthritis, with co-primary endpoints in weight loss and pain reduction.
In immunology, Lilly has announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. The company reports that the combination met the primary endpoint and all key secondary endpoints, supporting an integrated approach to treating psoriatic arthritis and obesity.
Oncology news includes updated EMBER-3 data for Inluriyo (imlunestrant) as monotherapy and in combination with Verzenio (abemaciclib) in ER-positive, HER2-negative advanced breast cancer, and Phase 3 BRUIN CLL-313 results showing that Jaypirca (pirtobrutinib) significantly reduced the risk of progression or death versus chemoimmunotherapy in treatment-naïve CLL/SLL without 17p deletions.
Corporate and strategic news items cover Lilly’s planned acquisition of Ventyx Biosciences, completion of the Adverum Biotechnologies tender offer, a strategic collaboration with Aktis Oncology, and a major manufacturing investment in a new active pharmaceutical ingredient facility in Huntsville, Alabama. Investors and observers can use this news feed to monitor clinical milestones, regulatory submissions, acquisitions, collaborations, financing activities and manufacturing expansions related to LLY.
Eli Lilly (NYSE: LLY) presented Phase 2 TRAILBLAZER-ALZ results, confirming that donanemab significantly slows cognitive decline in early Alzheimer's patients. The study demonstrated a 32% decline in the Integrated Alzheimer's Disease Rating Scale compared to placebo at 76 weeks, with notable amyloid plaque clearance. Secondary endpoints showed a 20-40% decline across various cognitive measures. Despite a 26.7% incidence of amyloid-related imaging abnormalities, ongoing discussions with regulators are promising, enhancing donanemab's potential for disease modification.
Eli Lilly and Company (NYSE: LLY) announced participation in the 2021 AACR Annual Meeting with presentations from its oncology portfolio. Highlights include data on Retevmo® (selpercatinib) for RET fusion-positive cancers beyond lung and thyroid cancers. The company will also showcase preclinical data for a selective estrogen receptor degrader, a BCL2 inhibitor, and next-generation KRAS-G12C and RET inhibitors. Retevmo received FDA’s Accelerated Approval last May, and further studies are aimed at expanding its application in various cancer types.
Eli Lilly reports promising results from the BLAZE-1 Phase 3 study, showing that bamlanivimab and etesevimab significantly lower COVID-19 hospitalizations and deaths in high-risk patients. Among 769 participants, the combination treatment led to an 87% reduction in events compared to placebo. No deaths occurred in the treatment group, while 15 occurred in the placebo group. The FDA and EMA support the emergency use of these treatments, emphasizing their potential as a life-saving option against COVID-19, especially with emerging variants.
Eli Lilly (NYSE: LLY) will present new data from ten studies at the virtual AD/PD 2021 conference from March 9-14, 2021. The TRAILBLAZER-ALZ phase 2 study demonstrated that donanemab significantly slowed cognitive decline in early symptomatic Alzheimer's patients compared to placebo. The conference will highlight Lilly's commitment to developing disease-modifying therapies and diagnostics for Alzheimer's disease, which currently affects over 50 million globally. The company aims to enhance early diagnosis and treatment options for this complex illness.
Eli Lilly and Company (NYSE: LLY) announced the retirement of two executive committee members: Myles O'Neill, senior VP of manufacturing operations, effective May 2, 2021, and Melissa Barnes, chief ethics and compliance officer, effective June 27, 2021. Edgardo Hernandez will succeed O'Neill, bringing extensive manufacturing experience, while Alonzo Weems will take over for Barnes, enhancing compliance and risk management. CEO David Ricks highlighted the executives' legacies and the potential growth under the new leadership.
Eli Lilly and Company (NYSE: LLY) has entered a research collaboration with Biolojic Design Ltd. to explore a novel antibody-based therapy for diabetes. The agreement includes research fees and the potential for Biolojic to earn up to $121 million in development milestones. Lilly's approach involves leveraging Biolojic's AI-driven multibody platform, designed to enhance therapeutic precision. Both companies aim to innovate diabetes treatment, with no changes to Lilly's 2021 financial guidance anticipated from this partnership.
Eli Lilly and Company (NYSE: LLY) will participate in the Barclays Global Healthcare Conference on March 9, 2021. Patrik Jonsson, senior vice president and chief customer officer, will engage in a virtual fireside chat at 9:45 a.m. ET. A live audio webcast will be available on Lilly's Investor website, and a replay will be accessible for about 90 days. Lilly is dedicated to creating high-quality medicines and improving disease management globally. For more information, visit www.lilly.com.
Eli Lilly announced a positive scientific opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for bamlanivimab alone and in combination with etesevimab. These therapies are recommended for treating COVID-19 in patients aged 12 and older at high risk of severe disease, who do not require supplemental oxygen. Data from the BLAZE-1 trial indicated a 70% reduction in hospitalizations. Lilly aims to provide affordable access globally, especially in low- and middle-income countries, while emphasizing that these treatments are not FDA-approved and carry potential risks.
Loxo Oncology at Lilly announced the publication of data from the pirtobrutinib (LOXO-305) global Phase 1/2 BRUIN clinical trial in relapsed chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and other non-Hodgkin lymphomas. Published in The Lancet, findings from the trial demonstrate safety and efficacy across 323 patients. The company plans to initiate four global Phase 3 studies in 2021 to further advance pirtobrutinib’s development, addressing unmet therapeutic needs in patients previously treated with standard care options.
Tirzepatide, from Eli Lilly (NYSE: LLY), demonstrated superior reductions in A1C and body weight compared to semaglutide in the 40-week SURPASS-2 trial involving 1,879 adults with type 2 diabetes. The 15 mg dose of tirzepatide achieved a 2.46% reduction in A1C and a weight loss of 12.4 kg. Notably, 51% of participants on 15 mg reached an A1C below 5.7%, outpacing semaglutide's 20%. Safety profiles were similar, primarily showing gastrointestinal-related adverse events. These results indicate the potential of tirzepatide as a leading treatment option for managing type 2 diabetes.